Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y, Sumrall A, Khatib Z, Mueller S, Kline C, Zaky W, Khatua S, Weathers SP, Odia Y, Niazi TN, Daghistani D, Cherrick I, Korones D, Karajannis MA, Kong XT, Minturn J, Waanders A, Arillaga-Romany I, Batchelor T, Wen PY, Merdinger K, Schalop L, Stogniew M, Allen JE, Oster W, Mehta MP.

J Neurooncol. 2019 Oct;145(1):97-105. doi: 10.1007/s11060-019-03271-3. Epub 2019 Aug 27.

PMID:
31456142
2.

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.

Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, Rostami E, Gudjonsson O, Shaw BL, Cahill DP, Galanis E, Barker FG 2nd, Santagata S, Brastianos PK.

Cancer. 2019 Sep 1;125(17):2910-2914. doi: 10.1002/cncr.32197. Epub 2019 Jul 17. No abstract available.

PMID:
31314136
3.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP.

J Neurosurg Pediatr. 2019 Apr 5:1-7. doi: 10.3171/2019.2.PEDS18480. [Epub ahead of print]

PMID:
30952114
4.

Core curriculum guidelines for a required clinical neurology experience.

Safdieh JE, Govindarajan R, Gelb DJ, Odia Y, Soni M.

Neurology. 2019 Mar 26;92(13):619-626. doi: 10.1212/WNL.0000000000007187. Epub 2019 Feb 22. Erratum in: Neurology. 2019 Jul 16;93(3):135.

5.

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.

Gay LM, Kim S, Fedorchak K, Kundranda M, Odia Y, Nangia C, Battiste J, Colon-Otero G, Powell S, Russell J, Elvin JA, Vergilio JA, Suh J, Ali SM, Stephens PJ, Miller VA, Ross JS.

Oncologist. 2017 Jul;22(7):834-842. doi: 10.1634/theoncologist.2016-0287. Epub 2017 May 11.

6.
7.

Electrographic Correlates of Plateau Waves in Patients With Leptomeningeal Metastases.

Gold CA, Odom N, Srinivasan S, Schaff L, Haggiagi A, Odia Y.

Neurohospitalist. 2016 Oct;6(4):161-166. Epub 2016 May 11.

8.

Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.

Donovan LE, Arnal AV, Wang SH, Odia Y.

CNS Oncol. 2016 Oct;5(4):203-9. doi: 10.2217/cns-2016-0011. Epub 2016 Sep 12.

9.

A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.

Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, Fine HA.

CNS Oncol. 2016;5(2):59-67. doi: 10.2217/cns-2015-0010. Epub 2016 Feb 10.

10.

A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.

Odia Y, Iwamoto FM, Moustakas A, Fraum TJ, Salgado CA, Li A, Kreisl TN, Sul J, Butman JA, Fine HA.

J Neurooncol. 2016 Mar;127(1):127-35. doi: 10.1007/s11060-015-2020-x. Epub 2015 Dec 7.

PMID:
26643807
11.

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

Odia Y, Kreisl TN, Aregawi D, Innis EK, Fine HA.

J Neurooncol. 2015 Oct;125(1):191-5. doi: 10.1007/s11060-015-1894-y. Epub 2015 Aug 19.

PMID:
26285768
12.

Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.

Odia Y, Varma H, Tsankova NM.

Clin Neuropathol. 2015 Sep-Oct;34(5):282-7. doi: 10.5414/NP300832.

PMID:
25907263
13.

Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma.

Gold CA, Lassman AB, Odia Y.

J Neurooncol. 2015 Jun;123(2):315-6. doi: 10.1007/s11060-015-1783-4. Epub 2015 Apr 12. No abstract available.

PMID:
25864100
14.

Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.

Odia Y, Shih JH, Kreisl TN, Fine HA.

J Neurooncol. 2014 Nov;120(2):431-40. doi: 10.1007/s11060-014-1571-6. Epub 2014 Aug 7.

PMID:
25098701
15.

A glioblastoma neurosphere line with alternative lengthening of telomeres.

Heaphy CM, Schreck KC, Raabe E, Mao XG, An P, Chu Q, Poh W, Jiao Y, Rodriguez FJ, Odia Y, Meeker AK, Eberhart CG.

Acta Neuropathol. 2013 Oct;126(4):607-8. No abstract available.

16.

cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.

Odia Y, Orr BA, Bell WR, Eberhart CG, Rodriguez FJ.

J Neurooncol. 2013 Nov;115(2):249-59. doi: 10.1007/s11060-013-1221-4. Epub 2013 Aug 11.

17.

LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program.

Mao XG, Hütt-Cabezas M, Orr BA, Weingart M, Taylor I, Rajan AK, Odia Y, Kahlert U, Maciaczyk J, Nikkhah G, Eberhart CG, Raabe EH.

Oncotarget. 2013 Jul;4(7):1050-64.

18.

Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.

Nguyen DN, Heaphy CM, de Wilde RF, Orr BA, Odia Y, Eberhart CG, Meeker AK, Rodriguez FJ.

Brain Pathol. 2013 May;23(3):237-43. doi: 10.1111/j.1750-3639.2012.00630.x. Epub 2012 Sep 24.

19.

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA.

Neuro Oncol. 2011 Oct;13(10):1143-50. doi: 10.1093/neuonc/nor091. Epub 2011 Aug 24.

20.

Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth.

Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG.

J Neuropathol Exp Neurol. 2011 Jul;70(7):568-77. doi: 10.1097/NEN.0b013e31821ff8d8.

Supplemental Content

Support Center